• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding Div RTS (OP:RHHVF)

419.72 +17.50 (+4.35%)
Streaming Delayed Price Updated: 12:24 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 951
Open 427.87
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 402.22
Today's Range 388.34 - 427.87
52wk Range 300.15 - 490.33
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion ↗
Today 12:25 EDT
GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff. 
Via MarketBeat
Topics Intellectual Property
News headline image
Sarepta Therapeutics Inc.: Why it's a rising gene therapy star
January 23, 2024
Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a leading commercial-stage biotech focused on developing precision gene therapy treatments for rare diseases. 
Via MarketBeat

Performance

YTD
+3.9%
+3.9%
1 Month
+2.2%
+2.2%
3 Month
-1.6%
-1.6%
6 Month
+3.8%
+3.8%
1 Year
+27.6%
+27.6%

More News

Read More
News headline image
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M ↗
January 02, 2024
Via Benzinga
News headline image
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial ↗
December 11, 2023
Via Benzinga
News headline image
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗
December 05, 2023
Via Benzinga
News headline image
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs ↗
December 04, 2023
Via Benzinga
News headline image
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗
October 31, 2023
Via Benzinga
News headline image
Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗
October 19, 2023
Via Benzinga
News headline image
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗
October 17, 2023
Via Benzinga
News headline image
Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗
October 11, 2023
Via Benzinga
News headline image
Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗
September 27, 2023
Via Benzinga
News headline image
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗
September 21, 2023
Via Benzinga
News headline image
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗
September 07, 2023
Via Benzinga
News headline image
Roche's Approved Lung Cancer Drug Beats Chemo In Rare Type Of Lung Cancer ↗
September 01, 2023
Via Benzinga
News headline image
Cancer Treatment In 7 Minutes: UK's Health Service To Rollout Roche's Tencentriq Injection Cutting Treatment Time ↗
August 30, 2023
Via Benzinga
News headline image
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗
August 23, 2023
Via Benzinga
News headline image
Roche's Accidental Lung Cancer Trial Data Leak: Shows Encouraging Early Data From Combination Therapy Study ↗
August 23, 2023
Via Benzinga
News headline image
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients ↗
August 21, 2023
Via Benzinga
News headline image
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗
July 28, 2023
Via Benzinga
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
July 26, 2023
Via Benzinga
News headline image
Alnylam Inks Co-Development, Co-Commercialization Pact With Roche For Hypertension Therapy ↗
July 24, 2023
Via Benzinga
News headline image
Nvidia Invested $50 million into This AI Drug Discovery Biotech
July 17, 2023
Via MarketBeat
Topics Artificial Intelligence
News headline image
Republican Presidential Candidate Vivek Ramaswamy Founded Roivant In Discussions With Roche For $7B Stomach Disease(s) Drug Deal ↗
July 14, 2023
Via Benzinga
News headline image
Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗
July 13, 2023
Via Benzinga
News headline image
Agilent Technologies Stock: Ready to Rise off the Floor
June 21, 2023
Via MarketBeat

Frequently Asked Questions

Is Roche Holding Div RTS publicly traded?
Yes, Roche Holding Div RTS is publicly traded.
What exchange does Roche Holding Div RTS trade on?
Roche Holding Div RTS trades on the OTC Traded
What is the ticker symbol for Roche Holding Div RTS?
The ticker symbol for Roche Holding Div RTS is RHHVF on the OTC Traded
What is the current price of Roche Holding Div RTS?
The current price of Roche Holding Div RTS is 419.72
When was Roche Holding Div RTS last traded?
The last trade of Roche Holding Div RTS was at 06/11/26 12:24 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap